Do ACE inhibitors or ARBs limit restenosis after stenting? --assimilating the data.
Ellis
S G
SG
Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F-25, Cleveland, OH, 44195, USA. elliss@ccf.org
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000628:therapy*; D006801:Humans; D012008:Recurrence; D013777:Tetrazoles / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine